| Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. | |
| | |
MedLine Citation:
|
PMID: 11180026 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Moxifloxacin is a new fluoroquinolone. In vitro studies have suggested that it could prolong ventricular repolarization. The main objective of this study was to measure the actual effect of single oral doses of moxifloxacin on QT interval duration in healthy volunteers. METHODS: Nine men and 9 women participated in a double-blind, randomized, placebo-controlled, crossover study. Each participant received single oral doses (400 mg and 800 mg) of moxifloxacin or placebo. At the time of expected moxifloxacin maximum concentration, several electrocardiographic recordings were obtained at rest and during the course of a submaximal exercise test. QT interval and the corresponding RR interval value were measured within a wide range of RR intervals in each subject. RESULTS: ANOVA showed that both moxifloxacin doses increased mean QT intervals compared with placebo. The mean QT interval duration at RR = 1000 ms was 379 +/- 24 ms during placebo, 394 +/- 33 ms during moxifloxacin 400 mg (P < .05), and 396 +/- 28 ms during moxifloxacin 800 mg (P < .05). Moxifloxacin-induced QT interval prolongation remained significant at all tested heart rates. The increase in QT interval duration relative to placebo remained between 2.3% +/- 2.8% and 4.5% + 3.8% across the range of RR intervals tested. CONCLUSION: Moxifloxacin prolongs QT interval duration. The amplitude of this effect is small, and the risk of moxifloxacin-induced torsades de pointes is expected to be minimal when the drug is administered at the recommended dose of 400 mg/d. However, moxifloxacin should not be used in patients with predisposing factors of torsades de pointes such as electrolyte disturbances and bradycardia or during coadministration of proarrhythmic drugs. |
| | |
Authors:
|
J L Démolis; D Kubitza; L Tennezé; C Funck-Brentano |
Related Documents
:
|
10665496 - No acute antimigraine efficacy of cp-122,288, a highly potent inhibitor of neurogenic i... 8071036 - A double-blind study of iopromide 300 for peripheral arteriography. results of a multi-... 16144536 - Defining success in clinical trials--profiling pregabalin, the newest aed. 3966006 - Initial treatment of parkinsonism with 8-alpha-amino-ergoline. 11984856 - Measurement of dopamine transporter occupancy for multiple injections of cocaine using ... 18695266 - Partial recovery of the endothelial glycocalyx upon rosuvastatin therapy in patients wi... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical pharmacology and therapeutics Volume: 68 ISSN: 0009-9236 ISO Abbreviation: Clin. Pharmacol. Ther. Publication Date: 2000 Dec |
Date Detail:
|
Created Date: 2001-01-12 Completed Date: 2001-01-18 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0372741 Medline TA: Clin Pharmacol Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 658-66 Citation Subset: AIM; IM |
Affiliation:
|
Department of Pharmacology, Saint-Antoine University Hospital, Paris, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adult Anti-Infective Agents / adverse effects*, blood, pharmacokinetics Aza Compounds* Cross-Over Studies Dose-Response Relationship, Drug Double-Blind Method Electrocardiography / drug effects Exercise Test / drug effects Female Fluoroquinolones* Heart Conduction System / drug effects, physiology Humans Infusions, Intravenous Male Placebos Quinolines* Ventricular Function / drug effects*, physiology |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Infective Agents; 0/Aza Compounds; 0/Fluoroquinolones; 0/Placebos; 0/Quinolines; 0/moxifloxacin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect r...
Next Document: Randomized placebo-controlled trial of the activity of the morphine glucuronides.